Authors






Matt Lashey, MBA

Latest:

Riding the Wave Through Chemo: Cancer Journey Leads to chemoWave App for Reporting PROs

"It is time for patients to have more control over what is prescribed to them and technologies like chemoWave are giving them that power." A cancer diagnosis leads to chemoWave, an app for recording patient-reported outcomes.




Glen T. Schumock, PharmD, PhD, MBA

Latest:

Adherence Patterns 1 Year After Initiation of SGLT2 Inhibitors: Results of a National Cohort Study

This article describes the trajectory of adherence patterns among users of sodium-glucose cotransporter 2 (SGLT2) inhibitors. The authors found that baseline factors were unable to predict the adherence trajectory groups.


Sally Wade, MPH

Latest:

Two-Year Adherence and Costs for Biologic Therapy for Rheumatoid Arthritis

Adherence to newly initiated biologic therapy for rheumatoid arthritis is important for long-term adherence.


Antonia V. Bennett, MA

Latest:

Identifying High-risk Asthma With Utilization Data: A Revised HEDIS Definition

A revised HEDIS definition of high-risk asthma more precisely identifies patients with functional impairment and higher healthcare utilization who might benefit from case management.


Aakashi Shah, MD

Latest:

The Association of Health Literacy Domains With Hospitalizations and Mortality

Despite previous research evidence, this study did not reveal an overall association of health literacy, numeracy, and graph literacy with all-cause hospitalizations or mortality.


Larry Massie, MD

Latest:

A System-Based Intervention to Improve Colorectal Cancer Screening Uptake

Using an electronic health record to identify and implement colorectal cancer screening in a population of eligible patients achieved higher uptake than a visit-based approach.





Ming-Chin Yang, DrPH

Latest:

Can Cancer Patients Seeking a Second Opinion Get Better Care?

Colorectal resection patients in Taiwan with heavy hospital shopping behaviors got better surgical care than those who did not shop or hospitals.





David W. Plocher, MD

Latest:

Plan Designs That Encourage the Use of Generic Drugs Over Brand-Name Drugs: An Analysis of a Free Generic Benefit

Small increases and decreases in pharmacy copayments have little influence on patients’ switching to generic drugs or on improving adherence to medication regimens.





Chi-Chen Chen, PhD

Latest:

Reexamining the Association of Care Continuity and Health Care Outcomes

Claims-based and patient-reported continuity measures have distinct effects on subjective and objective outcomes. A claims-based continuity indicator may be a unique dimension of care continuity.


Brigitte C. Madrian, PhD

Latest:

Testimonials Do Not Convert Patients From Brand to Generic Medication

We conducted a randomized controlled trial to assess whether adding a peer testimonial to a mailing increases conversion rates from brand name prescription medications to lower-cost equivalents.




Sara C. Erickson, PharmD

Latest:

Adherence, Persistence, and Switching Patterns of Dabigatran Etexilate

We present a descriptive analysis utilizing pharmacy claims from a managed care population to quantify adherence, persistence, and switching patterns for patients initiating dabigatran.


Jacob Reider, MD

Latest:

The Health Information Technology Special Issue: Has IT Become a Mandatory Part of Health and Healthcare?

The 7th annual Health Information Technology (IT) issue provides a window into how health IT tools are working well, how they may not be working as intended, and what we can do to continue making progress toward optimal use of technology to accomplish our shared goals: better health, better care experience, and lower per capita cost.


Michael Curry, MD

Latest:

Changing Demographics Among Populations Prescribed HCV Treatment, 2013-2017

From 2013 to 2017, the population of US patients prescribed treatment for chronic hepatitis C virus (HCV) changed, becoming predominantly treatment-naïve and having received care in nonacademic centers.

AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo